925-P: Participation in Daily Physical Activity (PA) Improves Glycemic Control in Youth with T1D

Aim: PA is an important part of diabetes management. ADA recommends that youth with T1D participate daily in ≥60 minutes of moderate to vigorous PA. We prospectively assessed daily PA in youth with T1D and compared demographic and diabetes variables according to frequency of PA ≥60 minutes/day. Methods: Youth (N=125, ages 8-17) with T1D completed 3-day PA records every 3 months for 18 months. Diabetes treatment data and A1c were collected at the same time. For each youth, we calculated the % of days with ≥60 minutes PA and compared those with ≥60 minutes PA on Results: Youth (50% male, 90% white, 74% pump-treated) had a mean±SD age 12.8±2.5 years, T1D duration 6.0±3.2 years, and A1c 8.2±0.9%. Youth had a median of 16 (IQR 12-17) PA record days. The % of days with ≥60 minutes PA ranged from 0 to 100% (median 53% [IQR 35-71%]), with 59% of youth reporting ≥60 minutes PA on ≥50% of days. Youth with ≥60 minutes PA on ≥50% of days were younger (12.4 vs. 13.5 years, p=.02), had shorter T1D duration (5.2 vs. 7.0 years, p=.002), lower daily insulin dose (0.86 vs. 1.00 u/kg, p=.002), and lower A1c (8.1 vs. 8.4%, p=.03) than youth with ≥60 minutes PA on Conclusion: A substantial proportion of youth with T1D do not exercise per recommendations. Given associations of PA with lower A1c, additional efforts to support exercise management in T1D are needed along with support for PA throughout the year. Disclosure R. O. La banca: None. L. K. Volkening: None. H. Desrochers: None. E. Dassau: Consultant; Self; Eli Lilly and Company, Employee; Self; Eli Lilly and Company, Research Support; Self; Dexcom, Inc., Tandem Diabetes Care, Speaker’s Bureau; Self; Dexcom, Inc., Roche Diabetes Care, Stock/Shareholder; Self; Eli Lilly and Company. S. N. Mehta: None. L. M. Laffel: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompe, Insulogic LLC, Janssen Pharmaceuticals, Inc., Laxmi Therapeutic Devices, LifeScan, Lilly Diabetes, Medtronic, Provention Bio, Inc. Funding National Institutes of Health (K12DK094721, P30DK036836); Iacocca Family Foundation